Central & Peripheral Action
Simultaneous GABA_A receptor modulation via Alprazolam and beta-adrenergic blockade via Propranolol eliminates both psychic fear and physical tremors.
MIGABET-PLUS is a synergistic neuropsychiatric formulation combining Propranolol Hydrochloride IP 20 mg with Alprazolam IP 0.25 mg by Blessme, Dellwich Lifescience LLP. Specifically formulated for patients suffering from generalized anxiety disorder with pronounced autonomic manifestations, situational performance anxiety, panic attacks with palpitations, and migraine prophylaxis complicated by stress.

Comprehensive pharmaceutical specifications, active API monograph compliance, dual receptor pharmacology, and 4x5x10 blister packaging details for MIGABET-PLUS.
MIGABET-PLUS unites 20 mg Propranolol with 0.25 mg Alprazolam. Formulated to provide rapid relief from both the emotional symptoms of anxiety (fear, worry) and the distressing physical symptoms (tachycardia, trembling, sweating).
In-depth pharmacological evaluation of Propranolol 20 mg + Alprazolam 0.25 mg tablets, marketed as MIGABET-PLUS by Blessme (Dellwich Lifescience LLP). Covers adrenergic-GABAergic synergy, migraine prevention, and pharmaceutical franchise availability across India.
MIGABET-PLUS is a dual-mechanism oral formulation uniting a non-selective beta-adrenergic antagonist (Propranolol 20 mg) with a high-affinity positive allosteric GABA_A modulator (Alprazolam 0.25 mg).
Anxiety frequently manifests as a vicious cycle: mental worry triggers peripheral adrenaline release, causing palpitations and trembling, which in turn amplifies psychic terror. MIGABET-PLUS breaks this feedback loop at both ends—Alprazolam quiets the mind while Propranolol shields the body from autonomic storm.
Approved neurological and psychiatric indications for MIGABET-PLUS include:
Alprazolam 0.25 mg acts centrally on GABAA receptor-chloride channels in the amygdala, cerebral cortex, and hippocampus. By enhancing inhibitory GABA neurotransmission, it produces rapid tranquility, diminishes anticipatory dread, and relieves emotional tension.
Concurrently, Propranolol 20 mg is a lipophilic non-selective beta-1 and beta-2 adrenergic antagonist that crosses the blood-brain barrier. In the periphery, it blocks beta-1 receptors in cardiac tissue to lower heart rate and myocardial contractility, preventing tachycardia and palpitations. It blocks beta-2 receptors in skeletal muscle to suppress hand tremors and reduces cranial vasodilation, providing robust prophylaxis against vascular migraine attacks.
Advantages of the Propranolol-Alprazolam combination:
MIGABET-PLUS must be taken strictly in accordance with medical advice:
MIGABET-PLUS contains Alprazolam, which carries potential for dependence and habit formation with prolonged therapy. Contraindicated in bronchial asthma, severe COPD, sinus bradycardia, and cardiogenic shock. Do not consume alcohol during therapy. Dispensed strictly against a valid medical prescription.
MIGABET-PLUS is manufactured in WHO-GMP certified facilities adhering to Schedule M protocols, ensuring micro-blend homogeneity, exact active content, and superior packaging stability.
Simultaneous GABA_A receptor modulation via Alprazolam and beta-adrenergic blockade via Propranolol eliminates both psychic fear and physical tremors.
Tropicalized 4x5x10 blister strips protect sensitive active APIs from moisture ingress and photodegradation, maintaining 36-month stability across all Indian zones.
Every batch is verified through authenticated Certificates of Analysis (COA), HPLC active assay validation, and dissolution profiles complying with IP standards.
Produced in state-of-the-art cleanroom manufacturing units in Gujarat adhering to automated compression, online check-weighing, and Good Laboratory Practices (GLP).
Prescribing guidance, contraindications, and drug interactions for Propranolol 20 mg + Alprazolam 0.25 mg tablets.
MIGABET-PLUS is a Schedule H / Narcotic prescription drug. Not for OTC sale. Do not consume alcohol during therapy. Exercise caution when driving or operating machinery.
Approved neurological and psychiatric indications for MIGABET-PLUS:
Key contraindications and monitoring requirements:
Dellwich Lifescience LLP is an established pharmaceutical company based in Science City, Ahmedabad, Gujarat, dedicated to advanced formulation technology, uncompromising quality assurance, and ethical healthcare supply. Through our specialized neurology division, Blessme, we manufacture and market superior neuro-psychiatric treatments, including MIGABET-PLUS (Propranolol 20 mg + Alprazolam 0.25 mg Tablets).
We support PCD pharma franchise partners, hospital supply chains, and contract manufacturing clients across India with guaranteed supply security, validated product dossiers, and prompt dispatch.
Whether you are seeking MIGABET-PLUS for district monopoly PCD franchise distribution, third-party contract manufacturing, or hospital bulk procurement, Dellwich Lifescience LLP delivers dependable supply and competitive trade margins.
Secure district-level monopoly marketing rights for MIGABET-PLUS and the complete Blessme neuropsychiatry range with visual aids, product glossaries, and promotional input support.
Turnkey manufacturing solutions for pharmaceutical marketing companies with flexible batch runs, rapid production turnaround, and full regulatory dossier support from Ahmedabad.
Direct bulk pharmaceutical supply agreements for multispecialty hospital chains, psychiatric nursing homes, and institutional medical tenders with prompt pan-India logistics.
When sourcing Propranolol Alprazolam tablets in India, MIGABET-PLUS by Blessme provides exceptional clinical efficacy, reliable blister packaging, and comprehensive B2B franchise support.
Manufactured in accredited facilities using IP grade active APIs, ensuring exact active content uniformity and fast dissolution.
Tamper-evident, moisture-resistant blister strips protect tablets from ambient humidity and transport friction.
Direct factory dispatch with GST invoicing, verified batch COA, and dependable logistics coverage across all Indian states.
Exclusive district-level franchise rights for MIGABET-PLUS and the Blessme portfolio with promotional visual aids.
Certificates of Analysis (COA), stability testing data, and MSDS readily available for institutional audits and tenders.
Direct access to Dellwich Lifescience product specialists for quick quotes, customized bulk orders, and customer assistance.
Authoritative answers to clinical, commercial, dosage, and regulatory questions regarding Propranolol + Alprazolam tablets.
MIGABET-PLUS is an oral prescription tablet from the Blessme division of Dellwich Lifescience. It contains Propranolol Hydrochloride IP 20 mg and Alprazolam IP 0.25 mg, formulated to treat acute anxiety states with prominent autonomic symptoms (palpitations, tremors, tachycardia) and for migraine prophylaxis associated with stress.
Alprazolam 0.25 mg acts centrally on GABA_A receptors to quench psychic fear, worrying thoughts, and panic. Simultaneously, Propranolol 20 mg blocks peripheral beta-adrenergic receptors, stopping the physiological adrenaline surge that causes rapid heart rate, chest pounding, sweating, and hand shaking.
MIGABET-PLUS is prescribed for Generalized Anxiety Disorder with somatic symptoms, situational/performance anxiety (stage fright), panic attacks with cardiac symptoms, tremor suppression, and migraine headache prophylaxis in patients with comorbid anxiety.
Both active ingredients are rapidly absorbed. Alprazolam achieves peak central anxiolysis within 1 to 2 hours, while Propranolol provides noticeable reduction in heart rate and trembling within 60 to 90 minutes.
No. Propranolol is contraindicated in patients with bronchial asthma, severe COPD, sinus bradycardia (heart rate below 50 bpm), second- or third-degree heart block, or cardiogenic shock, as it can cause bronchospasm and further lower heart rate.
Yes. Due to Alprazolam's sedative properties and Propranolol's blood pressure-lowering effect, mild drowsiness, fatigue, or dizziness can occur. Patients should avoid driving or operating machinery until their individual tolerance is established.
Alcohol is strictly prohibited. Combining alcohol with Alprazolam and Propranolol causes dangerous additive central nervous system depression, excessive hypotension, and profound sedation.
The Alprazolam component carries risk of tolerance and psychological or physical dependence when taken continuously over extended periods. Clinicians typically prescribe it for short durations or on an as-needed basis.
No. Abrupt stoppage can lead to severe rebound anxiety, insomnia, and withdrawal symptoms from Alprazolam, as well as rebound tachycardia or blood pressure spikes from sudden beta-blocker cessation. A gradual tapering schedule is essential.
MIGABET-PLUS is contraindicated during pregnancy unless specifically evaluated by a medical specialist, as both Alprazolam and Propranolol can cross the placenta and pose risks to the developing fetus.
MIGABET-PLUS is supplied in 4x5x10 blister strips (200 tablets per box) manufactured with tropicalized high-barrier foil to guarantee extended shelf life across all Indian climate conditions.
Pharmaceutical distributors and stockists can submit an enquiry through our online form below or contact our neuropsychiatry franchise desk at +91 99099 31992 for monopoly territory allocation.
Yes. Dellwich Lifescience provides turnkey contract manufacturing for Propranolol + Alprazolam tablets with WHO-GMP certification, customized branding, and fast dispatch from Ahmedabad.
Dellwich Lifescience LLP is headquartered on Science City Road, Ahmedabad, Gujarat, India, with rapid nationwide logistics connections.
Connect directly with Dellwich Lifescience LLP for trade pricing, district monopoly PCD rights, third-party manufacturing, or institutional hospital tender supplies.
Get wholesale pricing, PCD franchise monopoly rights, and technical documentation for Propranolol 20 mg + Alprazolam 0.25 mg Tablets.